3α-Hydroxy-7-oxo-5β-Cholanic Acid CAS 4651-67-6 Purity >99.5% (HPLC) Obeticholic Acid Intermediate Factory

Short Description:

Chemical Name: 3α-Hydroxy-7-oxo-5β-Cholanic Acid

CAS: 4651-67-6

Purity: >99.5% (HPLC)

White to Off-White Crystalline Powder or Powder

Intermediate of Obeticholic Acid (CAS: 459789-99-2)

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of 3α-Hydroxy-7-oxo-5β-Cholanic Acid (CAS: 4651-67-6) with high quality, commercial production. We can provide COA, worldwide delivery, small and bulk quantities available. Please contact: alvin@ruifuchem.com

Chemical Properties:

Chemical Name	3α-Hydroxy-7-oxo-5β-Cholanic Acid
Synonyms	3α-Hydroxy-7-keto-5β-Cholanic Acid; 3alpha-Hydroxy-7-oxo-5beta-Cholanic Acid; 7-Ketolithocholic Acid; Ursodeoxycholic Acid EP Impurity F
CAS Number	4651-67-6
CAT Number	RF-PI1988
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C24H38O4
Molecular Weight	390.56
Density	1.124±0.060 g/cm3
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	White to Off-White Crystalline Powder or Powder; No Foreign Substance, No Obvious Odor
Purity / Analysis Method	>99.5% (HPLC)
Melting Point	201.0~205.0℃
Loss on Drying	<0.50%
Residue on Ignition	<0.20%
Related Substances
Single Impurity	<0.50%
Total Impurities	<0.50%
Heavy Metals	≤10ppm
Proton NMR Spectrum	Conforms to Structure
Test Standard	Enterprise Standard
Usage	Intermediate of Obeticholic Acid (CAS: 459789-99-2)

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

FAQ:

Application:

3α-Hydroxy-7-oxo-5β-Cholanic Acid (CAS: 4651-67-6) is an intermediate of Obeticholic Acid (CAS: 459789-99-2). Obeticholic Acid is also called 6-Ethylchenodeoxycholic acid. Obeticholic Acid is a new derivative of chenodeoxycholic acid (CDCA) in human primary bile acids, a natural ligand for farnesoid x receptors (FXR). Obeticholic Acid was developed by American pharmaceutical company Intercept as the first drug to treat cholestatic liver disease in 20 years, and it is administered on patients that do not respond well to or cannot tolerate the old standard treatment drug ursodeoxycholic acid. Obeticholic Acid has also been tested to treat a more common form of fatty liver – non-alcoholic fatty liver disease (NAFLD). Obeticholic Acid can also be developed to treat other liver and intestine diseases.